Akurit 4 Tablet

Akurit 4 Tablet

Uses

• Tuberculosis Treatment: Akurit 4 is commonly prescribed as part of the initial intensive phase of tuberculosis treatment, targeting active TB infections.

How Akurit 4 Works

• Isoniazid and Rifampicin: These antibiotics kill actively growing bacteria and are highly effective against Mycobacterium tuberculosis.
• Ethambutol: Prevents bacterial cell wall formation, stopping the bacteria from multiplying.
• Pyrazinamide: Eliminates dormant bacteria and enhances the effects of other TB medications.

Common Side Effects

• Nausea, vomiting, and upset stomach
• Reddish-orange discoloration of body fluids (due to Rifampicin)
• Loss of appetite
• Joint pain (arthralgia)
• Vision disturbances (rare, from Ethambutol)

Serious Side Effects (Seek Medical Attention)

• Liver toxicity (jaundice, dark urine, abdominal pain)
• Severe skin reactions or allergies
• Visual impairment or loss of vision (due to Ethambutol)
• Peripheral neuropathy (nerve tingling or pain from Isoniazid)

Key Features

• Combines four potent anti-TB medications in a single tablet for effective treatment.
• Targets both active and dormant forms of tuberculosis bacteria.
• Part of the standard tuberculosis treatment regimen to ensure rapid bacterial eradication.

Frequently Asked Questions (FAQ)

1. Is Akurit 4 Tablet safe for pregnant women? The use of Akurit 4 during pregnancy should be strictly supervised by a healthcare provider, weighing potential benefits and risks.
2. How should I take Akurit 4? Take it on an empty stomach, 1 hour before or 2 hours after meals, or as directed by your doctor.
3. What precautions should I follow? Regular liver function tests are recommended during treatment. Inform your doctor if you experience yellowing of the skin, dark urine, or persistent fatigue.

References

1. Tuberculosis Treatment Guidelines - World Health Organization (WHO) Available from: https://www.medicines.org.uk/emc/product/2999/smpc
2. Akurit Product Information - National TB Control Program Available from: https://rsc.niaid.nih.gov/sites/default/files/Rifampicin%20Isoniazid%20Pyrazinamide%20Ethambutol%20PI_dated%20October%202018.pdf